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fraction).The dose was calculated based on 3D CT-planning 
using Oncentra Master Plan and PLATO planning software. 
Dose volume constrains which were analyzed for target were: 
V100, V150, V200, D90. Patients were monitored weekly 
during radiotherapy and 1,3,6,9 and 15 months after the end 
of the treatment and then at three months interval. Follow-
up visit included physical examination, images: ultrasound of 
abdomen and chest X ray and CEA value assessment. The 
acute toxicities were graded according to the EORTC/RTOG 
scales. 
Results: Median follow up was 34,4 months (range 18-58). 
Three local recurrences were observed. One patient died of 
intercurrent disease 12 months after the implantation which 
was unrelated to the brachytherapy. Grade 1 and 2 rectal 
toxicity was reported in ten patients ( 66,7%). Four patients 
(26.6%) reported Grade 3 toxicity. One patient (6,7%) 
required hospitalization and surgical intervention. The most 
common rectal symptoms were pain, bleeding, thin stool, 
rectal urgency and frequency and acute proctitis. However 
no fatal toxicity was observed. 
Conclusions: HDR brachytherapy is a valid anal sphincter 
sparing treatment modality to carefully selected patients and 
can be successfully used for salvage in patients with no other 
treatment options. The treatment was well tolerated by 
majority of patients with acceptable degree of acute 
toxicities. Overall survival data need longer follow-up. 
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Purpose/Objective: develop a method of intraluminal 
radiotherapy for esophageal cancer. 
Materials and Methods: In RCRC 52 inoperable patients with 
esophageal cancer were treated with the use of 1 step 
method intraluminal radiotherapy esophagus. In 63.4% of 
patients - constrictive inoperable esophageal cancer, at 
36.6% - a recurrence of esophageal cancer after treatment. 
Morphologically, the tumor shows squamous cell carcinoma 
(55.8%) and adenocarcinoma of varying degrees of 
differentiation (44.2%). In 84.6% of cases of marked 
dysphagia II-IV degree. Conducting topometricheskogo 
planning endovascular office allows you to set the Intrastat 
for the intraluminal radiotherapy in residual lumen of the 
esophagus to 1mm. Irradiation is performed with high activity 
sources Ir192. Dosing at 1 cm from the active line, the length 
of the active line 5-16sm. Treatment is carried out in 3 
fractions with an interval of 6-7 days ROD = 7Gr SOD = 
35games. In 96.2% of patients treated as outpatients 
conducted. After a 2-week break in 80.8% of cases to pursue 
further therapy: 52% rate teletherapy ROD = 2g = 80iGr to 
SOD, in 28.8% of cases in combination with chemotherapy. 
Follow-up of 4-26 months. In all cases observed treatment 
effect (tumor resorption in 23.1% - the complete destruction 
of the tumor, reducing the severity of dysphagia). 
Complications: 23.1% of the cases of different severity of 
esophagitis (docked conservative), 1.9% (1 patient) - 
esophago-tracheal fistula (setting 'covering' nitinol stent). 
Results: Follow-up of 4-26 months. In all cases observed 
treatment effect (tumor resorption in 23.1% - the complete 
destruction of the tumor, reducing the severity of 
dysphagia). Complications: 23.1% of the cases of different 
severity of esophagitis (docked conservative), 1.9% (1 
patient) - esophago-tracheal fistula (setting 'covering' nitinol 
stent). 
Carrying on 1 stage esophageal intraluminal radiotherapy 
reduces the severity of dysphagia, which contributes to the 
correction of metabolic disorders and improve the overall 
condition, creates the possibility of external beam 
radiotherapy and chemotherapy in patients previously 
considered incurable, and consequently improves the results 
of treatment. 
Conclusions: Intraluminal radiotherapy of the esophagus is a 
highly effective and safe treatment for patients with 
inoperable cancer of the esophagus, especially combines with 
dysphagia tumor genesis, significantly improving the quality 
of life and its duration in these patients. 
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Purpose/Objective: The purpose of this study is to compare 
high frequency ultrasonography (HFUS) and histpathologic 
assessment done by punch biopsy to determine depth of basal 
cell carcinoma (BCC), in both superficial and nodular BCCs 
prior to brachytherapy treatment. 
Materials and Methods: This study includes 20 patients with 
10 superficial and 10 nodular BCCs. First, punch biopsy was 
done to confirm the diagnosis and to measure tumour depth 
(Breslow rate). Subsequently, HFUS was done to measure 
tumour depth to search for correlation of these two 
techniques. 
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Results: Neither clear tendency nor significance of the punch 
biopsy vs. HFUS depth determination is observed. Depth 
value differences with both modalities resulted patient 
dependent and then consequence of its uncertainty. 
Conceptually, HFUS should determine the macroscopic lesion 
(gross tumour volume or GTV) while punch biopsy is able to 
detect the microscopic extension (clinical target volume or 
CTV). Uncertainties of HFUS are difficult to address while 
punch biopsy is done just on a small lesion section, not 
necessarily the deepest one. 
 
 
Conclusions: According to the results, HFUS is less accurate 
at very shallow depths. Nodular cases present higher depth 
determination differences than superficial ones. In our 
clinical practice, we decided to prescribe at 3 mm depth 
when HFUS measurements give depth lesion values smaller 
than this value. 
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Purpose/Objective: Malignant obstructive jaundice (MOJ) 
due to extraepatic cholangiocarcinoma (ECC) is relieved by 
stenting via endoscopic retrograde cholangiopancreatography 
(ERCP) or percutaneous transhepatic cholangiography and 
biliary drainage (PTCD). Nevertheless, stent occlusion rates 
of 30-45% have been reported in literature due to tumour 
ingrowth or overgrowth. Brachytherapy seem to increase the 
patency of the stent. We retrospectively evaluated the 
feasibility of intraluminal brachytherapy (ILBT) and its role in 
preventing stent blockage. 
Materials and Methods: All patients unsuitable for surgery or 
inoperable because of poor general conditions affected by 
ECC with MOJ receiving PTCD or ERCP followed by self 
expanding metallic stent (SEMS) placement were enrolled. 
The clinical chart were reviewed retrospectively. After the 
bilirubin level reduction, HDR-Ir192 ILBT was performed by 
delivering the dose prescribed at 1 cm from central axis of 
the catheter. ILBT regimen included fractional doses of 5Gy 
given over 4-5 consecutive days for a total dose of 20-25Gy. A 
2D or 3D planning were expected . Stent patency duration 
was defined as duration between PTCD or ERCP procedures 
and detection of elevated bilirubin level (>50% of nadir value) 
after ILBT.  
Results: From November 2005 to August 2014, 14 patients 
were treated. Only 1 patient underwent external beam 
radiotherapy (total dose of 45 Gy in 25 fractions) combined 
with chemotherapy (gemcitabine 300 mg / m2 / iv / week) 
followed by ILBT (10 Gy / 2 fractions/ 2 days), while the 
remaining patients received ILBT alone with palliative intent 
(5Gy for 4 or 5 fractions). Six patients had a histologically 
confirmed diagnosis of adenocarcinoma, while the remaining 
8 patients had an instrumental diagnosis, nevertheless two 
consecutive biopsy of the tumour. Patient characteristics are 
as follows: 7 M and 7 F, median age at diagnosis 75 years 
(range 65-84), median performance status, assessed by the 
Karnofsky scale, 60% (range 50-90%). Twelve patients had 
Klatskin IV, 1 Klatskin IIIa and 1 Klatskin II. Main symptoms 
prior to brachytherapy were jaundice and abdominal pain, 
while, from a laboratory point of view, all patients had 
abnormalities of liver function tests typical of MOJ. All 
patients completed the scheduled treatment with mild acute 
toxicity; 3 patients developed cholangitis after ILBT, treated 
with antibiotic therapy. The stent remained patent until his 
death in 12 out of 14 patients (median 15.5 months, range 3-
96). At a median follow-up of 18.5 months (3-96 months) 11 
patients died due to disease progression, and only 3 are alive 
with stable disease.  
Conclusions: Intraluminal brachytherapy post PTCD or ERCP 
self expanding metallic stent (SEMS) placement seems to be 
feasible and effective in preventing stent occlusion. Our 
purpose is to confirm these results in a larger series. 
 
 
 
 
 
 
